Featured Opinions
Decency as a Driver of Excellence
Dr Nicola Davies speaks to Mette Aagaard Hertz, Corporate Vice President at Novo Nordisk and Head of Human Resources in Research and Development, about pharma’s responsibility to maintain high standards in the fight against global health problems.
Patient centricity – from hubris to humility
In January I was ‘treated’ by 10 HCPs in 7 days and more than 100 patients in 24 hours. The medics managed my physical state; the patients guided my psychological well-being, helping me reach decisions and an understanding more readily by sharing their information and experiences.
Rethinking Pharma Part 3: Why Pharma are Giving Away the Golden Goose
In the 3rd installment of Rethinking pharma, Dr Andree Bates talks about value creation and why she thinks pharma is giving its value away.
Patient Associations are not customers!
by David Laws
With all of the hype and attention around patient centricity and the need to engage patients (customers) in their health, many folks in pharma are rushing to engage with patient associations like never before.
by Marc Yates
One of the brightest emerging market prospects with a model healthcare system… or an overstretched, under-regulated system on the verge of crisis? In this month’s column, I consider both sides of the Colombian story.
by Jeff Elton
As we enter a new year, the focus on real world advanced analytics, value as an expected basis for pricing and reimbursement, and services as a means to value will accelerate.
Insights from the World’s Largest Healthcare Market
New columnist, Jeffrey Frick shares insights on the Chinese healthcare market.
IDNs - What Pharma Needs to Know
One of the most rapidly emerging trends in healthcare is the formation of integrated delivery networks (IDNs). Manufacturers must understand what sets these large networks apart from traditional providers.
Rethinking Pharma Part 2: Why the Clinical Trial Process Must Change
The clinical trial process is a costly and integral part of bringing a drug to market, but does it have to be carried out the way it is currently? Is there a better way?
Adherence Programs: What works?
by Kevin Dolgin
What seperates successful adherence programs from unsuccessful ones?
by Jeff Elton
Investment in real-world data, advanced analytics, and value-delivering services by life sciences companies is growing rapidly, particularly in the US and Europe. These companies are changing their commercial operating models as they attempt to improve patient and health system value outcomes.
Aging in China: The Implications for Healthcare
by Marc Yates
China’s population has aged much faster than other populations, and this rapid aging poses challenges to healthcare, among which the most common are a surging healthcare expenditure and a rising difficulty in managing the 'iron triangle'.
Patients in 2014: the successes, the stories, the surprises
We reflect on the past 12 months from the patient perspective – it has been a phenomenal year of successes, stories and surprises.
Business model innovation won't happen until we do things differently
by David Laws
Customer Centricity, Communities of Practice, Big Data, Patient Centricity (probably), The Digital Organization and many more business model innovations have failed to take serious hold in pharma over the years.
Deirdre Coleman speaks to Pelin Icil, Marketing Manager, Bayer Healthcare (Women’s Health) about what women want and expect from pharma companies and Bayer’s newly launched Women’s Health TV.
What Patient Centric Leadership Looks Like
by Paul Simms
Paul Simms talks to Gitte P. Aabo, President & CEO of LEO Pharma, about patient centricity, new solutions within dermatology, partnerships and what the future holds.
by Kevin Dolgin
Hello all.It's been a few months since my last column, but I have a great excuse... I've been really, really busy.Anyway, the kind and insistent people at eyeforpharma have asked me if I could pick up where I left off and I'm quite happy to do so.
We are all patient-centric now — aren't we?
With patient centricity firmly on the agenda, what is true patient centricity and how can we translate the intent to align more with action? I interviewed executives at Novo Nordisk and Sanofi to highlight the three key things to consider when seeking to be patient centric.
by Marc Yates
In 2009 the Brazilian government passed the Generics Drugs Act; one of numerous initiatives intended to reduce spend on originator branded drugs, whilst boosting generic drug prescription and supporting the domestic drug industry.
Is Your Commercial Operation Ready for Healthcare 2.0?
The healthcare delivery market is undergoing dramatic change, adapting to survive in a much tougher business climate we call Healthcare 2.0. This should prompt pharma organizations to reevaluate the assumptions on which they’ve built their commercial model, or they risk falling behind the curve.
Rethinking Pharma Part 1: How Precision Medicine is Changing the Game
Dr Andree Bates looks at the impact of precision medicine on pharma and the change in mindset necessary to fit this new reality.
Putting the ‘me’ into medicine
This is the first of a new monthly column addressing patient centricity and the transition to consumerized medicine and points to lessons that can be learned from the entertainment, luxury goods and retail industries.
Exploring MINT: Part 4 - Turkey
by Marc Yates
In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Turkey.
Implementing disruptive selling skills
by Ifti Ahmed
A definition of madness is doing the same thing and expecting different results.
Do You Make These Strategic Planning Mistakes?
There is an epidemic of sticking roughly to the previous year's plan and budget. This may be useful if that approach is getting you to be the top brand, but if your results are not radically improving you need to examine both your strategy and budget allocation carefully.